UNSPSC 51285408: Cefmatilen

This classification denotes a cephalosporin antibiotic with the molecular formula C15H17ClN8O6S4, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier PA4O9CKP1M, chemically known as (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-(2H-triazol-4-ylsulfanylmethylsulfanyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid but more generally known as cefmatilen, which bears U.S. National Institutes of Health Compound Identifier 9690121. The term CEFMATILEN is an International Non-Proprietary Name or INN.

CEFMATILEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(CC1=C(N2C(OC1)C(OC)(NC(=O)CSC(F)F)C2=O)C(=O)O)C1N(NNN1)CCO.

UNSPSC 51285408 Cefmatilen, a Commodity code, does not align with the state and local procurement activity currently tagged under it. The code nominally describes a specific pharmaceutical ingredient, but recent solicitations show state and local governments buying naloxone, first-aid supplies, generic pharmaceuticals, and over-the-counter products through diverse procurement mechanisms — none of which reference cefmatilen. The mismatch suggests either tagging error at the point of solicitation posting or the code's misapplication to broader pharmacy and medical-supply procurement. If the intent is to track pharmaceutical ingredient sourcing, the code shows little relevant recent activity; if the goal is to monitor state and local medical and pharmacy product procurement generally, the code assignment does not reflect the work being bought.

Recent opportunities show state health departments, county public health programs, and municipal fire departments procuring medical consumables, naloxone, and generic drug programs through RFPs, RFQs, and competitive ITBs. The Minnesota Department of Administration issued an RFP through the Multistate Cooperative Purchasing Alliance (MMCAP) on January 20, 2026 for generic pharmaceuticals and OTC products with responses due March 26, 2026; Seminole County, Florida released an IFB for naloxone and drug deactivation systems on June 30, 2026 with a July 26, 2023 deadline; and the City of Tampa issued an IFB for medical and first-aid supplies for its fire department rescue division on March 25, 2026 with a $700,000 estimated contract value and an SLBE set-aside. Texas Health and Human Services Commission posted an RFI on April 3, 2026 to explore direct-to-manufacturer pharmacy programs. Activity spans Florida, Minnesota, Texas, and Oregon, with issuing bodies including state health agencies, counties, municipalities, and cooperative purchasing alliances. The code's recent posting record does not support reliable vendor tracking under its nominal pharmaceutical-ingredient scope.